Peptide Atlas · Peptide

Semaglutide

Semaglutide is a glucagon-like peptide-1 analogue with two amino acid substitutions (Aib8, Arg34) and a fatty-acid derivatization at lysine 26, designed for high albumin affinity and once-weekly dosing.

established

provisional
PubChem 56843331
3 citations
0 discussions
0 followers

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Semaglutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
SUSTAIN-6 cardiovascular outcomes trial	established	pmid 27633186
STEP 1 trial in adults with overweight or obesity	established	pmid 33567185
Discovery of the once-weekly GLP-1 analogue semaglutide	preclinical	pmid 26308095

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.